News Sentiment

VCYT sentiment intelligence

Veracyte Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Diagnostics & Research Read-through group
Latest close 56.97 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 59

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-0.2% over one week, +20.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

A Look at Veracyte Inc (VCYT) After 5.1% Gain -- GF Value $38.30 vs Price $59.51

Market Reaction

Balanced read

58/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction -0.2% Price digesting
Trend fit Trend active 20.4% over four weeks
Fair value 79.6% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 24
Neutral 32
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 59
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingView 14
Market source 11
GuruFocus 6
simplywall.st 5
www.marketscreener.com 3
Moomoo 3
Stock Titan 3
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 15
Analyst action 11
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Investing.com Direct company coverage

Piper Sandler initiates Veracyte stock with overweight rating

Piper Sandler has initiated coverage on Veracyte (NASDAQ:VCYT) with an overweight rating and a price target of $66.00, citing the company's cash-generative diagnostics lab anchored by its Afirma and Decipher Prostate genomic classifiers. These products are expected to drive signi

Tone
Positive 70/100
Event
Analyst action
Published
15 Jul 2026 21:40
Source
Investing.com
www.marketscreener.com Direct company coverage

Piper Sandler Initiates Veracyte at Overweight With $66 Price Target

Piper Sandler has initiated coverage on Veracyte (NASDAQ: VCYT) with an Overweight rating and set a price target of $66. This news comes as Veracyte continues to expand its diagnostic test offerings for various cancers and respiratory diseases. The company was also recently added

Tone
Positive 74/100
Event
Analyst action
Published
15 Jul 2026 12:40
Source
www.marketscreener.com
GuruFocus Direct company coverage

VCYT Initiated Coverage by Piper Sandler -- Rating Overweight

Piper Sandler has initiated coverage on Veracyte (VCYT) with an Overweight rating and a price target of $66.00, reflecting a positive outlook on the genomic diagnostics company. However, GuruFocus indicates that VCYT is significantly overvalued by 47.8% compared to its intrinsic

Tone
Positive 63/100
Event
Analyst action
Published
15 Jul 2026 10:12
Source
GuruFocus
Moomoo Direct company coverage

CCORF Maintains Veracyte(VCYT.US) With Hold Rating, Raises Target Price to $60

CCORF has reiterated its Hold rating on Veracyte (VCYT.US) while increasing the target price to $60. This adjustment reflects a continued cautious but not negative outlook on the company's stock performance.

Tone
Positive 66/100
Event
Analyst action
Published
15 Jul 2026 00:12
Source
Moomoo
Moomoo Direct company coverage

Press Release: Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026

Veracyte, Inc. (NASDAQ: VCYT) announced it will release its second quarter 2026 financial results on Wednesday, July 30, 2026, after the close of market. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss the results and provide a busin

Tone
Neutral 50/100
Event
Earnings
Published
10 Jul 2026 11:10
Source
Moomoo
GuruFocus Direct company coverage

VCYT Maintained by Morgan Stanley -- Price Target Raised to $47.

Morgan Stanley has maintained an "underweight" rating on Veracyte (VCYT) despite raising its price target to $47. The stock is currently trading 53.9% above its GF Value™ of $38.24, indicating it is overvalued. While VCYT has a strong GF Score™ of 75, driven by financial strength

Tone
Negative 40/100
Event
Analyst action
Published
09 Jul 2026 18:15
Source
GuruFocus
TradingView Direct company coverage

Veracyte, Inc. Stock 12‑Month Price Target Raised to $55.8, Implies 1% Downside

Veracyte, Inc.'s average 12-month stock price target has been increased from $54.8 to $55.8 by 10 analysts, with individual forecasts ranging from $42 to $70 per share. Based on the July 8 closing price, this new target suggests a potential 1% downside. The consensus rating from

Tone
Neutral 50/100
Event
Analyst action
Published
09 Jul 2026 13:15
Source
TradingView
Simply Wall Street Direct company coverage

Does Veracyte’s (VCYT) Russell Value Index Debut Redefine Its Small-Cap Defensive Narrative?

Veracyte (VCYT) was recently included in several Russell value and defensive indices, including the Russell 3000 Value and Russell 2000 Value-Defensive. While these inclusions may attract short-term investor interest and highlight a reclassification of the company, the core inves

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 06:40
Source
Simply Wall Street
AD HOC NEWS Direct company coverage

Veracyte Inc updates investors on breast cancer test coverage. Nasdaq-listed diagnostics group builds on genomic portfolio

Veracyte Inc is highlighting expanded Medicare coverage for its Prosigna breast cancer assay, a genomic test used to assess recurrence risk. This expansion is crucial for investors as Medicare decisions often influence other payers, potentially increasing test volumes and strengt

Tone
Positive 72/100
Event
Market update
Published
08 Jul 2026 17:39
Source
AD HOC NEWS
Market source Direct company coverage

A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.

Veracyte's Chief Accounting Officer, Jonathan Wygant, sold 24,000 shares for $1.1 million after exercising options, reducing his direct ownership by 34.57%. This transaction, along with a subsequent smaller sale, capitalized on the company's rising stock price driven by strong Q1

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 13:40
Source
Market source
TradingView Direct company coverage

Veracyte Stock Surges 117% in a Year: What's Driving the Rally?

Veracyte's stock has surged 117% over the past year, significantly outperforming its industry and the S&P 500, driven by its long-term growth strategy focusing on minimal residual disease testing, international expansion, and new product development. Key catalysts include strong

Tone
Positive 72/100
Event
Market update
Published
02 Jul 2026 18:12
Source
TradingView
www.marketscreener.com Direct company coverage

Veracyte, Inc.(NasdaqGM: VCYT) added to Russell 3000 Value Benchmark

Veracyte, Inc. (NasdaqGM: VCYT), a global diagnostics company, has been added to the Russell 3000 Value Benchmark. This news follows several other recent additions to various Russell indices, including the Russell 2000 Value, Russell 2000 Value-Defensive, and Russell 3000E Value

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 20:39
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Veracyte, Inc.(NasdaqGM: VCYT) added to Russell 2500 Value Benchmark

Veracyte, Inc. (VCYT) has been added to the Russell 2500 Value Benchmark, as well as several other Russell indices including the Russell 2000 Value Benchmark, Russell 2000 Value-Defensive Index, and Russell 3000 Value Benchmark. This inclusion signifies the company's recognition

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 19:39
Source
marketscreener.com
GuruFocus Direct company coverage

VCYT Maintained by Guggenheim -- Price Target Raised to $65

Guggenheim maintained a "Buy" rating for Veracyte (VCYT) and significantly increased its price target from $45.00 to $65.00, reflecting confidence in the company's future growth. Despite this positive analyst outlook and a strong GF Score™ of 75/100, GuruFocus indicates VCYT is 5

Tone
Positive 67/100
Event
Analyst action
Published
29 Jun 2026 15:41
Source
GuruFocus
Simply Wall Street Direct company coverage

Veracyte (VCYT) Enters Multiple Russell Indexes Is Its Small-Cap Profile Quietly Changing?

Veracyte (VCYT) has been added to several Russell indexes, including the Russell 2000 Defensive and Growth-Defensive, which could significantly increase its institutional investor base and trading liquidity. While this inclusion may boost awareness for the company's cancer diagno

Tone
Positive 67/100
Event
Balance sheet
Published
29 Jun 2026 14:41
Source
Simply Wall Street
TradingView Direct company coverage

Price to book forward of Veracyte, Inc. – NASDAQ:VCYT

This page from TradingView displays financial data for Veracyte, Inc. (NASDAQ: VCYT), specifically focusing on its Price to Book Forward metric. The content lists various financial tools and market data services provided by TradingView and its partners.

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 05:41
Source
TradingView
www.marketscreener.com Direct company coverage

Veracyte, Inc.(NasdaqGM: VCYT) added to Russell 2000 Value-Defensive Index

Veracyte, Inc. (NasdaqGM: VCYT), a global diagnostics company, has been added to the Russell 2000 Value-Defensive Index. The company provides various diagnostic tests for cancers previously mentioned in the article, such as thyroid cancer and breast cancer, and is developing test

Tone
Positive 70/100
Event
Market update
Published
28 Jun 2026 22:42
Source
www.marketscreener.com
TradingView Direct company coverage

Enterprise value to revenue forward of Veracyte, Inc. – FWB:12V

This article provides financial information for Veracyte, Inc. (FWB:12V) on TradingView, specifically focusing on its enterprise value to revenue forward. It indicates the market status as closed with no trades, and the content primarily consists of navigation and boilerplate inf

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 19:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Veracyte, Inc. – FWB:12V

This article provides financial information for Veracyte, Inc. (FWB:12V), specifically focusing on its price-to-sales forward metric. The data is sourced from exchanges and financial data providers, indicating that the market for this stock was closed with no trades recorded at t

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 18:41
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Veracyte, Inc. – NASDAQ:VCYT

This page provides financial information for Veracyte, Inc. (NASDAQ: VCYT), specifically focusing on its forward price-to-sales ratio. The content appears to be a financial data page from TradingView, offering an overview of the company's financials for investors and analysts. It

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 18:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Veracyte, Inc. – NASDAQ:VCYT

This article provides financial information for Veracyte, Inc. (NASDAQ: VCYT), specifically focusing on its enterprise value to EBIT forward. The content is presented within the TradingView platform, which offers various financial tools and data.

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 11:11
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Veracyte, Inc. – FWB:12V

This article provides financial information for Veracyte, Inc. (FWB:12V), focusing on its forward price-to-earnings ratio. It states that the market is currently closed with no trades recorded and offers data made by humans from various financial services.

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 04:10
Source
TradingView